At the EBMT 2025 Congress, Dr. Alice Bertaina (Stanford University, USA) presented encouraging Phase Ia data on T-allo10 immunotherapy following TCRαβ-depleted hematopoietic stem cell transplantation (HSCT) in pediatric and young adult patients with hematologic malignancies.
Key takeaways from the study included:
- 0% non-relapse mortality (NRM) at both 6 months and 1 year
- 100% leukemia-free survival (LFS) and GVHD-free, relapse-free survival (GRFS) in intermediate and high-dose cohorts
- Early detection of Tr1 cells post-infusion, contributing to immune tolerance and clinical efficacy
- 66.7% of patients met the immune reconstitution (IR) efficacy endpoint—more than double the historical benchmark
- Dose-dependent reduction in viral reactivations
- Enhanced CD4⁺ memory T-cell expansion and stronger cytokine responses compared to controls
These findings highlight the potential of T-allo10 to improve immune reconstitution and support durable leukemia control after HSCT.
Sincere congratulations to Dr. Bertaina and the Stanford University team for their continued leadership in advancing post-transplant immunotherapy for hematologic malignancies.
